Levesam Injection contains Levetiracetam 100mg, an antiepileptic agent indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby inhibiting abnormal neuronal firing and reducing seizure activity. This injectable formulation is intended for intravenous administration, providing an alternative route for patients unable to take oral medication or requiring rapid therapeutic levels. Levesam Injection is typically used as adjunctive therapy in adults and pediatric patients aged one month and older. The pharmacokinetic profile of levetiracetam is characterized by rapid absorption, minimal protein binding, and predominant renal excretion, necessitating dose adjustments in patients with renal impairment. Common adverse effects include somnolence, dizziness, headache, and fatigue, while serious reactions such as behavioral changes and hypersensitivity are rare but warrant monitoring. Levesam Injection should be administered under medical supervision with careful consideration of patient history, concomitant medications, and renal function. It is contraindicated in patients with known hypersensitivity to levetiracetam or any component of the formulation. Proper storage and handling as per manufacturer guidelines are essential to maintain product stability and efficacy.